systemic juvenile idiopathic arthritis
Rheumatology · 2011–2025
4decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tocilizumab Tocilizumab biosimilar requested for listing under the same circumstances as the reference brand Actemra for the treatment of active giant cell arteritis,… | Nov 2025 | Recommended with restriction | none received |
| tocilizumab Treatment of systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older. Extension of subcutaneous injection presentations (syringes and… | Mar 2020 | Recommended with restriction | unclear |
| canakinumab Treatment of systemic juvenile idiopathic arthritis (sJIA) in children and adults without polyarticular presentation who have failed to respond to previous… | Mar 2015 | Recommended with restriction | none received |
| tocilizumab Treatment of severe active systemic juvenile idiopathic arthritis in patients under 18 years of age, who meet certain criteria. | Nov 2011 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.